Prostaglandin E2 Enhances Human Cord Blood Stem Cell Xenotransplants and Shows Long-Term Safety in Preclinical Nonhuman Primate Transplant Models  by Goessling, Wolfram et al.
Cell Stem Cell
Clinical ProgressProstaglandin E2 Enhances Human Cord Blood Stem
Cell Xenotransplants and Shows Long-Term Safety
in Preclinical Nonhuman Primate Transplant Models
Wolfram Goessling,1,2 Robyn S. Allen,3 Xiao Guan,4 Ping Jin,5 Naoya Uchida,6 Michael Dovey,7 James M. Harris,7
Mark E. Metzger,3 Aylin C. Bonifacino,3 David Stroncek,5 Joseph Stegner,8 Myriam Armant,8 Thorsten Schlaeger,4
John F. Tisdale,6 Leonard I. Zon,2,4,9 Robert E. Donahue,3 and Trista E. North2,7,*
1Genetics and Gastroenterology Divisions, Brigham and Women’s Hospital, Gastrointestinal Cancer Center, Dana-Farber Cancer Institute,
Boston, MA 02115, USA
2Harvard Stem Cell Institute and Harvard Medical School, Boston, MA 02115, USA
3Hematology Branch, National Heart, Lung, and Blood Institute (NHLBI), NIH, Rockville, MD 20850, USA
4Stem Cell Program, Children’s Hospital, Boston, MA 02115, USA
5Department of Transfusion Medicine, Clinical Center, NIH, Bethesda, MD 20892, USA
6Molecular and Clinical Hematology Branch, National Heart, Lung, and Blood Institute (NHLBI)/National Institute of Diabetes and Digestive
and Kidney Diseases (NIDDK), NIH, Bethesda, MD 20892, USA
7Department of Pathology, Beth Israel Deaconess Medical Center, Boston, MA 02115, USA
8Center for Human Cell Therapy, Immune Disease Institute, Boston, MA 02115, USA
9Howard Hughes Medical Institute, Boston, MA 02115, USA
*Correspondence: tnorth@bidmc.harvard.edu
DOI 10.1016/j.stem.2011.02.003SUMMARY
Hematopoietic stem cells (HSCs) are used in trans-
plantation therapy to reconstitute the hematopoietic
system. Human cord blood (hCB) transplantation has
emerged as an attractive alternative treatment option
when traditional HSC sources are unavailable; how-
ever, the absolute number of hCBHSCs transplanted
is significantly lower than bone marrow or mobilized
peripheral blood stem cells (MPBSCs). We previ-
ously demonstrated that dimethyl-prostaglandin E2
(dmPGE2) increased HSCs in vertebrate models.
Here, we describe preclinical analyses of the thera-
peutic potential of dmPGE2 treatment by using
human and nonhuman primate HSCs. dmPGE2 sig-
nificantly increased total human hematopoietic
colony formation in vitro and enhanced engraftment
of unfractionated and CD34+ hCB after xeno-
transplantation. In nonhuman primate autologous
transplantation, dmPGE2-treated CD34+ MPBSCs
showed stable multilineage engraftment over 1 year
postinfusion. Together, our analyses indicated that
dmPGE2 mediates conserved responses in HSCs
from human and nonhuman primates and provided
sufficient preclinical information to support pro-
ceeding to an FDA-approved phase 1 clinical trial.
INTRODUCTION
HSCs alone possess the ability to both self-renew and differen-
tiate into all mature blood lineages, thereby maintaining immune
function, tissue perfusion, and hematopoietic homeostasisthroughout the lifetime of the organism. HSCs are therapeutically
valuable for transplantation in the treatment of hematologic
malignances. They are a rare population in the bone marrow
(BM), and methods for direct isolation and expansion of a pure
population of functional human HSCs remain elusive. The devel-
opment of therapeutic options to manipulate and maintain
human HSCs is of major clinical interest; however, to date, no
such therapy has proven effective in large-scale clinical trials.
HSC transplantation is the only curative option for many
patients with leukemia, lymphoma, or BM failure. Stem cells ob-
tained from the BM or peripheral blood (PB) must be human
leukocyte antigen (HLA) matched to the patient in order to avoid
rejection. Only 25%–30% of patients can utilize BM from
a related sibling donor, and matched unrelated donors cannot
be found in BM registries for all patients, particularly for those
from ethnic minorities (Laver et al., 2001). In the past two
decades, human cord blood (hCB) stem cells have emerged as
an option for unmatched patients, because they are readily ob-
tained in registries and have less stringent requirements for
HLA matching (Broxmeyer et al., 1989). The use of hCB trans-
plantation has steadily grown since the first transplant occurred
in 1988 to more than 20,000 recipients worldwide (Rocha and
Broxmeyer, 2010). In the United States, hCB transplants account
for almost 20% of all HSC transplants annually (Broxmeyer et al.,
2009); among minority populations, the number of hCB trans-
plants reaches 40% (Ballen et al., 2002). Because of limited
volume, the absolute number of HSCs available in hCB speci-
mens is only 10% of that utilized in traditional BM transplants,
leading to delayed engraftment and increased peritransplant
complications (Rocha and Broxmeyer, 2010). One approach to
alleviate this problem is to transplant two unrelated hCB speci-
mens (Ballen et al., 2007b). Although this change correlated
with improved adult engraftment rates, the time to engraftment
was not shortened; engraftment after a hCB transplant can
take >50% longer than traditional HSC transplants (BroxmeyerCell Stem Cell 8, 445–458, April 8, 2011 ª2011 Elsevier Inc. 445
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PGE2 Enhances Human HSCset al., 2009). The identification of agents to increase hCB HSC
homing, engraftment, or total stem cell number is of significant
therapeutic value.
Given this important clinical challenge, many investigators
have sought to accelerate hCB HSC engraftment and blood
count recovery after transplantation. The most clinically
advanced approach thus far appears to be short-term culture
with the notch ligand Delta (Delaney et al., 2010). This in vitro
expansion procedure has been evaluated with significant
evidence of success in an ongoing clinical trial; however, Delta
treatment may lead to the depletion of long-term engrafting
HSCs in the hCB unit, indicating that even this promising
approach could need modifications before it can be broadly em-
ployed. In vitro expansion potential has also been described for
insulin-like growth factor binding protein 2 in xenotransplanta-
tion studies (Zhang et al., 2008) and more recently for inhibition
of the aryl hydrocarbon receptor (Boitano et al., 2010). Short
ex vivo treatment of hCB with a chemical inhibitor of dipeptidyl-
peptidase IV (CD26) boosts homing to the hematopoietic niche
to enhance engraftment in xenotransplantation models (Camp-
bell et al., 2007). Rather than targeting HSCs, parathyroid
hormone (PTH) has been used in vivo to enhance engraftment
by modifying the murine osteoblastic HSC niche (Adams et al.,
2007); PTH has also been used to safely facilitate stem cell mobi-
lization in a clinical trial (Ballen et al., 2007a).
Murine hematopoietic transplantation assays are limited by
the relatively short life span of mice compared to humans,
enabling the detailed study of HSC function only over a limited
time window. This often requires secondary transplant experi-
ments to assess long-term HSC function, including self-renewal.
Nonhuman primates have emerged as a valuable vertebrate
model to perform longitudinal HSC transplantation studies.
Engraftment and expansion can be examined after autologous
transplantation of mobilized peripheral blood stem cells
(MPBSCs). Further, efficient viral transduction techniques,
utilizing fluorescent markers, allow the direct comparison of
differently treated, uniquely labeled cell populations in an
in vivo competitive transplantation assay (Donahue et al., 2005;
Uchida et al., 2009). Significantly, the life span of nonhuman
primates approaches that of humans, making it possible to study
the long-term effects of different treatment modalities on the
graft and host under conditions that approximate the demands
on the human hematopoietic system (Trobridge and Kiem, 2010).
We previously demonstrated that dmPGE2 increased HSC
number in vitro and in vivo (North et al., 2007). Murine limiting
dilution competitive transplantation analysis demonstrated a
2- to 4-fold increase in HSC number after short ex vivo dmPGE2
exposure, without impacting multilineage hematopoietic differ-
entiation or decreasing serial transplantation and self-renewal
potential (Hoggatt et al., 2009; North et al., 2007). dmPGE2 func-
tions through cAMP-mediated regulation of the Wnt signaling
pathway to control cell proliferation and apoptosis of HSCs
in vivo (Goessling et al., 2009). Recent work has expanded these
findings (Frisch et al., 2009; Hoggatt et al., 2009) to demonstrate
the ability of dmPGE2 to modulate the BM niche and enhance
homing.
Here, we present preclinical investigations of the safety and
therapeutic potential of ex vivo dmPGE2 treatment to enhance
human hematopoietic transplantation protocols. We found that446 Cell Stem Cell 8, 445–458, April 8, 2011 ª2011 Elsevier Inc.hCB HSCs differentially express PGE2 receptors, and dmPGE2
treatment elevates cAMP activity in human cells. In vitro,
dmPGE2 treatment of CD34+ hCB decreased apoptosis, while
significantly increasing HSC proliferation and hematopoietic
colony formation. Further, dmPGE2 treatment enhanced the
rates of human CD45+ chimerism in NOD/SCID mice xenotrans-
planted with whole or CD34+ hCB cells. By using CD34+
MPBSCs in a nonhuman primate (rhesus macaque) competitive
autologous transplantation scheme, we showed that dmPGE2
treatment has no negative impact on HSC function, including
multilineage repopulation, compared to matched controls at >1
year postinfusion. Human and rhesus MPBSCs had reduced
expression of EP2 and EP4 compared to hCB HSCs; however,
each exhibited dose-responsive increases in cAMP activity after
PGE2 treatment. Microarray gene expression analysis of human
and rhesus CD34+ MPBSCs revealed conserved regulation of
cell cycle, PGE2 pathway, and HSC-related genes, representing
a potential mechanism of action for dmPGE2; qPCR analysis of
hCB samples after dmPGE2 stimulation confirmed similar gene
regulation. These results predict that dmPGE2 will be safe for
use in clinical HSC transplantation protocols.
RESULTS
hCB HSCs Express PGE2 Receptors and Respond
to Exogenous PGE2 Stimulation
We, and others, have shown PGE2 enhances HSC engraftment
in isogenic murine transplantation models (Hoggatt et al.,
2009; North et al., 2007). To examine the therapeutic potential
of dmPGE2 for human HSC transplantation, we investigated
the safety and efficacy of ex vivo exposure of hCB HSCs. To
assess whether hCB was capable of responding to exogenous
PGE2 stimulation, subfractionated samples were examined for
the presence of each of the four PGE2 receptors. Quantitative
PCR (qPCR) was performedwith purified cell fractions contained
within the umbilical cord, i.e., CD34+, CD133+, or mononuclear
cells (MNC); human umbilical vein endothelial cells (HUVEC)
were used as a nonhemogenic control population. The CD34+
population predominantly expressed EP2 and EP4 (Figure 1A);
the level of EP4 expression is highly correlated with CD34+
status. EP2 and EP4 are similarly expressed in CD133+ hCB
HSCs. Analysis of the total hCB MNC population showed main-
tenance of EP2 expression, while EP4 was significantly downre-
gulated. In contrast, EP1 and EP3 are not significantly expressed
in any hCB populations. SCL andRUNX1were utilized to confirm
that the CD34+ and CD133+ hCB cell fractions contained HSCs
(Figure 1B).
Having established the distribution of PGE2 receptors in hCB,
the intracellular response to dmPGE2 stimulation was examined.
Upon ligand binding, EP2 and EP4, Gas-coupled protein recep-
tors, enhance intracellular cAMP levels (Regan et al., 1994) to
initiate signaling cascades. We have recently shown that
PGE2-mediated cAMP elevation regulates HSC number by
modification of Wnt activity in vitro and in vivo (Goessling et al.,
2009). To determine whether cAMP elevation would occur in
response to dmPGE2, whole hCB cells were exposed to
increasing doses of dmPGE2 for 5, 15, and 30 min. dmPGE2
caused a dose-dependent increase in cAMP in hCB cells (Fig-
ure 1C), which is similar to the cAMP activator forskolin. Given
Figure 1. hCB Expresses Prostaglandin Receptors and Responds to PGE2 Signaling
(A) CD34+ cells have the highest expression of PGE receptors, particularly EP4. n = 3; ANOVA, *p < 0.001, compared to other EPs, **p < 0.001, compared to other
hCB cells.
(B) CD34+ cells express the immature HSC markers SCL and RUNX1. n = 3; ANOVA, *p < 0.001, compared to other hCB cells.
(C and D) Total hCB (C) and CD34+ hCB (D) cells were incubated with increasing concentrations of dmPGE2 or forskolin and subjected to a luminescence-based
cAMP assay. cAMP levels increased in response to treatment (mean ± SD of 3–5 samples).
(E) Annexin V FACS analysis revealed that dmPGE2 exposure significantly decreased apoptotic CD34+ cells at 6 hr posttreatment compared to controls. n = 8,
t test; *p = 0.024.
(F) EdU incorporation measured by FACS was significantly enhanced in CD34+ cells in response to dmPGE2 exposure. n = 8; t test, *p = 0.006.
See also Figure S1.
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PGE2 Enhances Human HSCsthe enrichment of EP2 and EP4 receptors in the CD34+ popula-
tion, we directly examined cAMP responsiveness in this cell
fraction; interestingly, the effective dose response occurred at
a lower concentration in the CD34+ population (Figure 1D),possibly reflecting the high level of expression of EP4 on purified
hCB HSCs. Importantly, both unfractionated and CD34+ hCB
cells elicited rapid responses to dmPGE2 stimulation over the
dose range tested.Cell Stem Cell 8, 445–458, April 8, 2011 ª2011 Elsevier Inc. 447
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totic effect on murine HSCs (Goessling et al., 2009; Hoggatt
et al., 2009); to further analyze the conserved impact of dmPGE2
exposure, apoptosis and cell proliferation studies were con-
ducted. Pooled CD34+ hCB samples were thawed, split for
parallel processing, and treated with 1 mM dmPGE2 or DMSO
vehicle control. At 3 and 6 hr after exposure, apoptosis was
measured by AnnexinV FACS analysis. Both treatment cohorts
demonstrated similar levels of apoptotic cell death at 3 hr;
however, by 6 hr, cells treatedwith dmPGE2 showed a significant
reduction in apoptosis compared to controls (Figure 1E; Fig-
ure S1A available online). Complementary results were observed
for cellular proliferation, where PGE2 caused significant changes
in EdU incorporation at 6 hr after dmPGE2 treatment (Figure 1F;
Figure S1B).
dmPGE2 Enhances hCB HSC Function In Vitro
and In Vivo
dmPGE2was previously found to increase hematopoietic colony
formation of murine embryonic stem cells (ESCs) (Goessling
et al., 2009; North et al., 2007). To determine whether dmPGE2
exposure impacted the functional potential of hCB samples,
pooled CD34+ hCB cells were exposed to DMSO or dmPGE2
(1 mM) for fixed incubation periods (15, 30, 60, 180, 360 min),
then plated in triplicate on H4434 methylcellulose at limiting dilu-
tion (2000, 800, 320) (Figure 2A; Table S1). The majority of hema-
topoietic colony types increased in response to dmPGE2; in
particular, the GEMM population was significantly elevated after
only 1 hr of dmPGE2 treatment. When colony numbers were
combined and normalized for initial plating density, differences
in total colonies across all replicates of the limiting dilution and
dose-response assay demonstrated a 1.4-fold enhancement
after dmPGE2 stimulation (Figure 2B). Together, the in vitro
CFU-C data strongly suggest that dmPGE2 enhances colony-
forming potential of CD34+ cells.
In limiting dilution competitive transplantation assays,
dmPGE2 significantly increased the multilineage serial trans-
plantable long-term repopulating ability of murine HSCs (Hog-
gatt et al., 2009; North et al., 2007). We examined the ability of
dmPGE2 to enhance hematopoietic engraftment of hCB stem
cells in vivo by using a xenotransplantation model. To mimic
clinical transplantation protocols, which primarily utilize unma-
nipulated (non-lineage-depleted, non-NK/T cell-depleted, non-
CD34-enriched) samples, and to assess the potential impact
on all cell populations contained within a hCB unit, whole hCB
samples were initially employed for xenotransplantation. Indi-
vidual hCB units were split to account for cord-to-cord alter-
ations in HSC content and viability, then treated in parallel
ex vivo with dmPGE2 (10 mM) or DMSO for 1 hr in dextran/
albumin suspension media; alterations in incubation time and
media from our original studies (North et al., 2007) did not impact
the effect of dmPGE2 stimulation in murine short-term CFU-S12
evaluations (Figures S2A and S2B). To best mimic clinical condi-
tions, recipient NOD/SCID mice were not conditioned to
enhance engraftment beyond a standard regimen to clear the
hematopoietic niche. After sublethal irradiation (6.5 Gy), NOD/
SCID mice were transplanted with either 20 million matched
dmPGE2-treated or control-treated whole hCB cells; this dose
was chosen to detect positive effects of dmPGE2 on human448 Cell Stem Cell 8, 445–458, April 8, 2011 ª2011 Elsevier Inc.chimerism in xenotransplant recipients based on prior whole
hCB studies (Trowbridge et al., 2006). Human PB chimerism
was evaluated by FACS analysis for hCD45; antibody reactivity
>1% was used to identify positively engrafted recipients (Fig-
ure S3A). At 1 and 3 months posttransplant, more recipients of
hCB cells treated ex vivo with dmPGE2 exhibited human
CD45+ hematopoietic repopulation than recipients of matched
controls, with overall higher average levels of PB chimerism
(Figures 2Cand2D). hCD45+BMengraftment >0.2%at 3months
posttransplantation was also higher in recipients of dmPGE2-
treated hCB (Figures 2C and 2D; Figure S3B). Multilineage anal-
ysis of mice with hCB BM engraftment values >1% revealed
contribution to each of themajor blood lineages and the absence
of lineage skewing in recipients of dmPGE2-treated cells; signif-
icant increases in the overall percentage of hCB-derived pheno-
typic stem/progenitor cells, myeloid, and T cell lineages were
observed compared to matched controls (Figures S4A–S4C).
Importantly, we were unable to detect any toxicity related to
ex vivo dmPGE2 treatment over the duration of analyses:
secondary transplants showed PB repopulation by PGE2-
treated hCB cells; no excessive cell death, leukemic transforma-
tion, or disproportional loss of murine hosts were observed
between recipients of dmPGE2-treated hCB and matched
controls; and histological analysis of tissue (skin, liver, spleen,
intestine, and bone) taken at the time of sacrifice showed no
differences in cellular morphology, architecture, or vascularity
from controls (data not shown).
To confirm whether the enhanced hCB engraftment was due
to direct effects on CD34+ HSCs and progenitors, fresh hCB
units were enriched by MACS for hCD34 and split for parallel
treatment with either dmPGE2 or DMSO control as indicated
above. 2500 CD34+ cells were transplanted per recipient; this
dose can provide repopulation without cytokine supplementa-
tion or the injection of ‘‘helper’’ cells, while testing the lower
end of engraftment efficiency. As seenwith whole hCB, dmPGE2
treatment led to a higher percentage of mice exhibiting hCD45+
PB and BM chimerism (Figures S5A and S5B). Our results
suggest that ex vivo treatment of whole hCB units with dmPGE2
will be safe and effective in achieving expansion of HSCs for
transplantation in the clinical setting because of preferential
targeting of the CD34+ population.
Human and Nonhuman Primate Mobilized Peripheral
Blood Stem Cells Can Functionally Respond
to dmPGE2 Treatment
To further assess the long-term safety of ex vivo dmPGE2 expo-
sure for clinical transplantation protocols, a nonhuman primate
model was employed. Because CB samples are not routinely
harvested from primates, safety evaluations were conducted
with CD34+ MPBSCs isolated after a G-CSF/SCF conditioning
protocol optimized for rhesus macaques (Donahue et al.,
2005). To assess the inherent ability of rhesus MPBSCs
(rhMPBSC) to respond to PGE2 stimulation, subfractionated
CD34+ samples were examined for the presence of each of
the four PGE2 receptors by qPCR; results were compared to
that observed on similarly mobilized human MPBSC (hMPBSC)
samples. CD34+ hMPBSCs predominantly expressed EP2 and
EP4 (Figure 3A); however, expression of EP4 in hMPBSC
was relatively equal to that of EP2, and unlike hCB HSCs
Figure 2. dmPGE2 Enhances hCB Proliferation In Vitro and Engraftment In Vivo
(A and B) CD34+ hCB cells were exposed to 1 mM dmPGE2 over a matrix of cell densities and exposure times.
(A) Colony formation at day 13 was enhanced after dmPGE2 exposure for 15 min to 6 hr; shown are the results of 800 cells/plate (n = 3).
(B) Normalization and combination of cell counts over all exposure times and cell densities revealed a significant increase in total colony number after dmPGE2
exposure (n = 45; t test, *p = 0.018).
(C and D) Whole hCB was transplanted into sublethally irradiated NOD/SCID mice. PB was analyzed at 1 and 3 months and recipient BM at R3 months
posttransplantation. Asterisk indicates results were statistically different from control.
(C) Individual hCD45+ chimerism values for mice receiving control (red squares) or dmPGE2-treated hCB (blue circles). Themean is indicated by a solid horizontal
line; a dashed line shows the 1%cut-off for positive engraftment. PB: 1month, control 0.94 ± 0.2414, dmPGE2 2.41 ± 0.4118; t test, p = 0.0017; 3months, control
0.76 ± 0.1418, dmPGE2 2.27 ± 0.3778; t test, p = 0.0004. BM: control 0.95 ± 0.4373, dmPGE2 3.70 ± 1.310; t test, p = 0.0348.
(D) Cumulative summary of the percent of NOC/SCID recipients engrafted with hCB. PB: 1 month, control 13/42, dmPGE2 27/46; Fisher’s exact, p = 0.011;
3 months, control 10/32, dmPGE2 23/28; Fisher’s exact, p = 0.018; BM: control 11/30, dmPGE2 23/36; Fisher’s exact, p = 0.047.
See also Figures S2–S5 and Table S1.
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qPCR analysis of rhMPBSCs revealed 5-fold lower EP receptor
expression in nonhuman primate HSCs than hMPBSCs, with
EP2 particularly underrepresented (Figure 3B). However, by
using the luminescent assay described above, dose-dependent
responses to dmPGE2were observed for bothMPBSCs popula-
tions; hMPBSC showed a comparable response to CD34+ hCB,
while rhMPBSC required a slightly higher dose for cAMP activa-
tion (Figures 3C and 3D). These data indicate that human and
rhesus CD34+ HSCs can react to dmPGE2.dmPGE2-Treated rhMPBSCs Show Stable Long-Term
Multilineage Engraftment in Nonhuman Primate
Competitive Transplantation Study
Receptor distribution and response assays suggested that the
nonhuman primate model would be relevant to assess the
potential long-term safety of the therapeutic use of dmPGE2.
To examine the functional impact of dmPGE2 exposure on
rhMBPSCs, a competitive autologous transplant study was per-
formed. A two-pronged design scheme was developed to inter-
nally control for compound treatment and vector transductionCell Stem Cell 8, 445–458, April 8, 2011 ª2011 Elsevier Inc. 449
Figure 3. PGE2 Receptors and cAMP Response Are Preserved between Human and Nonhuman Primate Peripheral Blood Stem Cells
PB stem cells were mobilized from humans and nonhuman primates.
(A) qPCR analysis showed that EP2 and EP4 are equally and predominantly expressed in hMPBSC. n = 3; ANOVA, *p < 0.001 EP2 or EP4 versus EP1 and EP3.
(B) qPCR revealed low EP receptor expression on rhesus MPBSC, with EP4 predominant. n = 3–6; ANOVA, *p < 0.001 versus EP1, 2; **p = 0.01 versus EP3.
(C and D) The cAMP response to dmPGE2 is preserved in human and rhesus MPBSC.
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were previously described in rhesus macaques (Uchida et al.,
2009). CD34+ rhMPBSCs were split for parallel processing and
treated ex vivo with 10 mM dmPGE2 or X-Vivo10 for 1 hr either
prior to or after transduction; dmPGE2 dose was selected based
on prior murine (North et al., 2007) and xenotransplant data.
Retroviral vectors expressing either EGFP or EYFP were trans-
duced in order to differentiate the treatment groups in vivo; treat-
ment/vector pairings were alternated between individuals to
control for potential protocol-related bias. Transduction efficien-
cies varied between primates but were similar for EGFP and
EYFP in each experiment (Table S2). Treated, differentially
labeled cells were combined and reinfused into each donor for
competitive repopulation analysis; PB samples were taken at
fixed intervals beginning at >2 weeks posttransplantation, and
the contribution of each labeled population followed via multili-
neage FACS analysis. Neither pre- nor posttransduction treat-
ment with dmPGE2 negatively affected the engraftment potential
of rhMPBSCs; both the percentage of total PB contribution of
dmPGE2-treated cells, and that of each lineage remained
present, stable, and comparable to controls at all time points
examined up to 1 year postreinfusion (Figures 4A and 4B; Fig-
ure S6). In all transplant recipients, reconstitution was uneventful
and no toxicity was observed; cells transduced with EGFP450 Cell Stem Cell 8, 445–458, April 8, 2011 ª2011 Elsevier Inc.showed greater PB engraftment than cells expressing EYFP,
regardless of treatment. dmPGE2 was demonstrated to be
safe to the long-term functional potential of rhMPBSCs.
Comparative Genomic Analysis of Human
and Nonhuman Primate CD34+ MPBSCs Exposed
to Increasing Doses of dmPGE2 Shows High
Conservation of Gene Expression
In order to identify the potential mechanism of action of dmPGE2
on gene expression and HSC function, and to possibly explain
the muted response of rhesus CD34+ MPBSCs to dmPGE2
exposure, microarray gene expression analysis was conducted.
Human and rhesus CD34+ MPBSCs were exposed to DMSO or
dmPGE2 (10 and 50 mM dose) and processed for microarray
analysis at 2, 6, and 12 hr posttreatment (Figure S7). 10 mM
dmPGE2 had minimal impact on gene expression in rhMPBSCs
compared to treatment at 50 mM, while significant changes were
observed at each dose with hMPBSCs (Figures 5A–5C). The
greatest relative alterations in gene expression were observed
for all treatments at 6 hr postexposure, so that time point was
utilized for further comparative analysis. 110 genes were
commonly regulated between human and rhesus MPBSCs,
indicating an evolutionarily conserved response to PGE2 stimu-
lation (Figure 5D; Table S3A); among this set were genes
Figure 4. dmPGE2 Exposure of Nonhuman Primate MPBSC Shows Long-Term Safety
(A) Whole PB and multilineage longitudinal FACS analysis of primates treated with dmPGE2 prior to transduction (n = 2). Equivalent long-term function of
fluorescently marked control (open circles) and dmPGE2-treated MPBSCs (solid circles) was shown.
(B) Whole PB and multilineage longitudinal FACS analysis of primates treated with dmPGE2 posttransduction (n = 3). Long-term survival and differentiation
capacity is maintained irrespective of compound exposure (as indicated above).
See also Figure S6 and Table S2.
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PDE4B, and PTGER2; several chemokines and cytokines
including CXCL1, CXCL3, CXCL10, IL1R1, IL18R1, IL23A, and
ANG; and many genes known to be specific to cell cycle regula-
tion or hematopoietic cell differentiation. 262 genes were simi-
larly regulated in human cells at both dmPGE2 doses (Figure 5D;
Table S3B) but not significantly altered in rhesus samples;
among these were many major regulators of HSC development
and maturation such as CXCR4, HHEX, HOXA9, JUNB, LCK,LMO2, LY6A, RUNX1, and TF. Considerable and exclusive over-
lap was also found between each of the PGE2 doses in human
cells and that of the high dose in rhesus macaques (Figure 5D;
Tables S3C and S3D); in particular, 10 mM hMPBSC/50 mM
rhMPBSC show coordinated upregulation of genes like FLT3,
JAK1, CCR1, andCD8a, perhaps indicative of enhanced prolifer-
ative and differentiation potential in the transplantation assays,
while 50 mM hMPBSC/50 mM rhMPBSC displayed common
regulation among genes influencing hematopoietic quiescenceCell Stem Cell 8, 445–458, April 8, 2011 ª2011 Elsevier Inc. 451
Figure 5. Genome-wide Expression Analysis Reveals Commonly Regulated Genes in Human and Rhesus MPBSCs
(A–C) Scatter plots show genes significantly up- and downregulated in response to dmPGE2 (x axis) compared to controls (y axis). Genes with >2-fold changes
are highlighted in red.
(D) Schematic display of genes regulated in response to dmPGE2 treatment, showing overlap between treatment groups of MPBSCs.
See also Figure S7 and Table S3.
Cell Stem Cell
PGE2 Enhances Human HSCssuch as ANGPT1, ATXN1, FOXO1, HIF1A, STAT3, and VAV1.
Together these data suggest that rhMPBSCmay require a higher
level of PGE2 stimulation for optimal HSC-related gene regula-
tion than hMPBSCs, correlating with receptor distribution and
transplant results.
PGE2 Regulates Common Signaling Pathways in Human
and Rhesus CD34+ MPBSC
To futher delineate the cellular signals mediated by dmPGE2, the
microarray data were subjected to ingenuity pathway analysis,
which revealed a number of commonly upregulated (24) and
downregulated (12) pathways across all treatment groups
and in pairwise comparisons (Figures 6A and 6B; Tables S4A
and S4B). Strikingly, among the upregulated gene sets, three of
the top five are directly influenced by cAMP-mediated signaling
cascades (Figure 6C), suggesting high conservation of imme-
diate early responses to PGE2 stimulation across vertebrate
species (Goessling et al., 2009); chemokine/cytokine-related
pathways were likewise represented by multiple gene families.
The significance of the downregulated pathways is less clear,452 Cell Stem Cell 8, 445–458, April 8, 2011 ª2011 Elsevier Inc.although several gene sets appear to be related to alternative
differentiation potential, including that of endothelial cells (Fig-
ure 6D). A roughly equal number of pathways were commonly
upregulated (17) and downregulated (18) in hMPBSCs treated
at varying dmPGE2 concentrations (Tables S5A and S5B).
Through ingenuity analysis, we again find that while many path-
ways are coordinately regulated between the 50 mM human
MPBSC and rhesus treatment groups (33 up, 7 down), a number
of pathways were conversely common only to the 10 mM PGE2
dose of hMPBSC and 50 mM PGE2 in rhesus macaques (11 up,
8 down) (Tables S6A, S6B, S7A, and S7B), indicating that
PGE2-stimulation potential of rhesus CD34+ MPBSCs may be
several fold lower than that of human CD34+ cells.
hCB Exposed to dmPGE2 Shows Gene Expression
Alterations in Cell Cycle, PGE2 Signaling,
and Stem Cell Behavior which Correlate
to the MPBSC Microarray Analysis
To validate the gene expression signatures observed in the
MPBSC analysis and to show conservation of the potential
Figure 6. Ingenuity Pathway Analysis Reveals Conserved Response Patterns between Human and Rhesus MPBSCs
Microarray data were subjected to ingenuity pathway analysis.
(A and B) Venn diagram illustrations of the overlap of significantly up- and downregulated signaling pathways between human and rhesus macaque MPBSCs.
(C and D) List of significantly up- and downregulated pathways common between human and rhesus dmPGE2-treatedMPBSCs; the ratio indicates the fraction of
affected genes of the number of total genes included in each pathway.
See also Tables S4–S7.
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PGE2 Enhances Human HSCsmechanism of action of dmPGE2 in hCB samples, we examined
relative changes in gene expression after 10 mM dmPGE2 treat-
ment at fixed intervals after exposure (1, 3, 6, and 9 hr) by qPCR.
To confirm that dmPGE2 was mediating effects on hCB cell
proliferation and apoptosis, we examined a panel of 10 cell
cycle-related genes (Figure 7A). As previously shown for murineHSCs, expression of the classical WNT-pathway target and
proproliferative cell cycle regulator, CYCLIN D1, increased after
PGE2 treatment;CYCLIN E1 showed a similar response. Expres-
sion of the antiapoptotic genes BCLXL and BCL2 were
enhanced by PGE2, while that of the proapoptotic gene BAX
decreased at 3 and 6 hr. These data suggest that oneCell Stem Cell 8, 445–458, April 8, 2011 ª2011 Elsevier Inc. 453
Figure 7. dmPGE2 Affects Expression of Cell Cycle, PGE2-Related, and HSC Genes
CD34+ hCB was incubated with 10 mM dmPGE2 over a range of 1–9 hr; results of qPCR analysis are shown. n = 3–5; ANOVA, *p < 0.001 versus all untreated
controls. *p < 0.001 versus control at corresponding time point.
(A) dmPGE2 exposure altered expression of genes related to cell cycle and apoptosis.
(B) dmPGE2 induced expression of PGE2 pathway-related genes.
(C) dmPGE2 affected genes associated with hematopoietic stem cell function.
Cell Stem Cell
PGE2 Enhances Human HSCsconsequence of dmPGE2 treatment may be to preserve hCB
cells in a viable state, capable of homing, engrafting, and prolif-
erating to repopulate the BM niche and reconstitute PB lineages.
We have previously shown that PGE2 not only enhances HSC
formation and function but also is required for the normal kinetics
of hematopoietic recovery (North et al., 2007). Clinical and
murine studies have demonstrated elevated levels of PGE2 after
hematopoietic transplantation (Ballinger et al., 2006; Cayeux454 Cell Stem Cell 8, 445–458, April 8, 2011 ª2011 Elsevier Inc.et al., 1993). Additionally, PGE2 is a well-characterized mediator
of inflammatory responses to injury, where we have recently
shown it can stimulate wnt activity and regeneration (Goessling
et al., 2009). While PGE2 is capable of binding its four cognate
receptors with high affinity, to rapidly elicit changes in cAMP-
mediated signaling, it has an extremely short serum half-life.
Here, after stimulation of CD34+ hCB cells with dmPGE2, we
find that several components related to PGE2 production and
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PGE2 Enhances Human HSCssignaling are specifically regulated (Figure 7B): dmPGE2 treat-
ment induces expression of prostaglandin synthesis enzymes
COX1 and 2, as well as the PGE-specific endoperoxidase
PTGES, which could thereby enable a perpetuation of PGE2-
mediated signaling. Conversely, the PGE2 receptors EP1 and
EP3, generally considered to be negative response elements,
were also upregulated in response to dmPGE2. These seemingly
opposing responses could serve as a means to ‘‘fine tune’’ the
extent and targets of PGE2-mediated signaling; similar counter-
regulatory responses have been observed for pathways that
partner with PGE2, such as WNT (Dichtel-Danjoy et al., 2009).
In support of this concept, correlative responses were also
observed for pathway components downstream of ligand
binding: the cAMP response element (CREM), as well as
phosphodiesterase 4D (PDE4D), which regulates the breakdown
of cAMP, were 13- and 3.8-fold upregulated, respectively.
To assess which factors critical to HSC formation and function
in a vascular niche, such as the umbilical cord,may be influenced
by dmPGE2 to positively impact CD34+ hCB cells, we conducted
qPCR expression analysis of matched samples after 10 mM
dmPGE2 treatment for a panel of 20 HSC-related genes identi-
fied in the literature and/or in the microarray analysis. CXCR4
expression was highly responsive to dmPGE2 exposure (Fig-
ure 7C), consistent with previous reports (Hoggatt et al., 2009).
Vascular endothelial growth factor (VEGF) is a potent stimulator
of endothelial andHSCproliferation, which regulates thematura-
tion of the vascular endothelial niche, thereby enabling HSC
induction from hemogenic endothelium (Gerber et al., 2002);
VEGF expression was robustly increased, 3.7-fold, by dmPGE2.
IL8 (CXCL8) is one of the inflammatory cytokines involved in
proliferation and migration of endothelial progenitors and HSCs
(Laterveer et al., 1995); IL8 expression increased up to 6-fold in
response to dmPGE2. N-cadherin, which has a controversial
role in adult HSC function (Li and Zon, 2010) but is expressed
in the arterial HSC niche, was elevated up to 8.5-fold after
dmPGE2 treatment. Expression of Bone-Morphogenic Protein-4
(BMP4), required to demarcate and specify the hemogenic
endothelial population in the arterial niche (Durand et al., 2007),
and that of Ephrin B2 (EPHB2), required for arterial niche identify
(Lawson et al., 2001), were 3.5-fold and >9-fold upregulated,
respectively. Expression of traditional markers of immature
HSCs such as RUNX1 (AML1) and SCL decreased over time in
untreated cells, consistent with the observation that HSCs
progressively dedifferentiate in culture; dmPGE2 limited the
loss ofRUNX1 expression and increased the expression of regu-
lators of quiescence such as FOXO1 (Tothova et al., 2007), sug-
gesting that it may enable the hCBHSCs tomaintain their identity
or bias HSCs toward self-renewal.
DISCUSSION
The data presented here suggest that ex vivo stimulation of
human HSCs with dmPGE2 prior to transplantation may posi-
tively impact gene expression, engraftment capacity, and HSC
function in the clinical setting. While advantageous in both its
availability and immunologic flexibility, hCB contains signifi-
cantly fewer HSCs than BM or mobilized PB. The development
of a rapid and safe means to enhance hCB HSC number and/
or function has been an area of significant research. The datapresented here and previously (Goessling et al., 2009; Hoggatt
et al., 2009; North et al., 2007) suggest that short ex vivo
dmPGE2 treatment can enhance several factors that should
improve human HSC function and multilineage hematopoietic
recovery including homing, apoptosis, and proliferation. Inter-
estingly, gene programs indicative of HSC production from
a vascular niche (VEGF, BMP4) are also significantly upregulated
or maintained (RUNX1) in response to dmPGE2 stimulation of
hCB. As the CD34 antigen is expressed on both HSCs and he-
mogenic endothelium, these data could imply that a portion of
the effect of PGE2 in hCB is mediated by endothelial cells, which
have recently been shown to provide signals that retain HSCs in
an undifferentiated state (Butler et al., 2010); dmPGE2 exposure
could alternatively promote the ‘‘budding’’ or transition of imma-
ture HSCs from hemogenic endothelial precursors, similar to the
original HSC screen in zebrafish (North et al., 2007). More work is
needed to examine these intriguing alternatives; however, the
maintenance of a significant number of PGE2-regulated gene
programsacrossspecies suggests that dmPGE2mayelicit bene-
ficial regulatory responses over multiple hematopoietic contexts.
As recently discussed (McDermott et al., 2010), despite years
of intensive investigation, the xenotransplantation model
remains an approximation of human engraftment potential. As
part of the preclinical evaluation of the safety of dmPGE2 for
ex vivo treatment of hCB, we made several selective choices in
the treatment scheme to optimize the potential to elucidate
any effects—positive or negative—of dmPGE2 on the hCB
sample. In particular, we chose to treat and transplant whole
cord blood samples, in addition to purified CD34+ cells; this
was done to mimic current clinical protocols, which use whole
hCB units, and to elucidate any unanticipated or unwanted
effects on non-HSC cell types contained in the cord. We
observed no significant differences in negative outcomes
between recipients of dmPGE2-treated versus control-treated
cords, with or without CD34 enrichment. Despite the positive
effect of dmPGE2 on both in vitro and in vivo models of hCB
HSC function, these assays still cannot directly account for the
variety of factors that influence the ultimate ability of a given
hCB sample to engraft. The immunological consequences of
HSC transplantation alone, notwithstanding the complexities
added by the use of two independent immune systems in the
setting of double cord transplantation, are still difficult to model;
the standard isogenic murine competitive transplantation
schemes do not account for immunological reactions, while
cross-species transplantation introduces rejection and engraft-
ment scenarios that do not exist in the clinical setting.Meaningful
xenotransplantation of two unmatched hCB units to fully illus-
trate advantageous treatment protocols is not possible at this
time because no specific criteria exist to reliably predict engraft-
ment success of each individual cord unit prior to use in trans-
plant assays.
The competitive autologous transplantation protocol in the
nonhuman primate model enables the comparison of dual-
treated, retrovirally marked HSC populations in vivo without
the confounding influences of immunorejection. Although these
experiments are resource intensive, prohibiting in vivo dose-
finding studies to demonstrate a statistically significant benefit
for dmPGE2, they allow for longitudinal evaluation of individual
primates to assess durability, functionality, and overall safetyCell Stem Cell 8, 445–458, April 8, 2011 ª2011 Elsevier Inc. 455
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with dmPGE2 prior to reinfusion are capable of contributing to
stable multilineage repopulation at time points more than 1
year postinjection, with an absence of any lineage skewing or
compromise of HSC self-renewal potential. Long-term
nonhuman primate transplantation experiments were initiated
with 10 mM dmPGE2 based on available safety and engraftment
data from murine (North et al., 2007) and xenotransplantation
models. While this treatment was not able to elicit a significant
enhancement in repopulation potential compared to matched
controls in the majority of rhesus macaques subjected to the
protocol utilized, the result most probably reflects suboptimal
compound dosing rather than the inability of dmPGE2 to elicit
functional responses in HSCs. Receptor distribution analysis
obtained while the primate studies were ongoing revealed
a significant difference in EP receptor expression between
human and nonhuman primate CD34+ HSCs. Further, while
10 mM dmPGE2 could elicit changes in cAMP activity, higher
doses caused more dramatic effects, and statistically meaning-
ful differences in gene expression were observed only at 50 mM
dmPGE2. We anticipate that use of 50 mM dmPGE2 in the trans-
plant protocol may cause a more discernable difference in repo-
pulation potential in the autologous transplantation assay, but
strong conservation of genetic regulation across species and
clear evidence of safety and efficacious results in alternate verte-
bratemodels preclude the justification of repeating these studies
in the nonhuman primate model to confirm these expectations.
Through our investigations, we identified EP4 as marker highly
enriched in the hCB CD34+ and CD133+ population. Additional
studies are needed to define whether EP4 could be used alone
or in combination to further refine the isolation of cells with
in vivo hCB HSC function. In the setting of clinical hematopoietic
transplantation, the entire hCB sample will be treated with
dmPGE2 ex vivo prior to transplant; the selective distribution
of EP4 indicates that despite the presence of multiple cell types
in thewhole hCB sample, themain effect of treatment is probably
focused on the stem and progenitor cell populations. The fact
that similar results were obtained for whole hCB and CD34+
cell xenotransplantation into NOD/SCID mice further supports
a targeted effect on nonlineage-specified cell types. The selec-
tive distribution of the EP4 receptor to the CD34+ population in
hCB samples will hopefully serve tominimize any potential nega-
tive side effects while mediating the full benefits of dmPGE2
stimulation on hematopoietic recovery in the clinical setting.
Many signaling pathways have been identified that regulate
aspects of both HSC production and adult homeostasis, but it
is unclear whether HSCs from a developmental vascular niche,
such as CD34+ hCB, will respond predictably to stimulation
from BM-derived factors in the clinic. No prospective study to
date has examined whether the simple process of stem cell
isolation prior to in vitro culture and transplantation may deprive
HSCs of factors normally produced by supporting cell types that
influence their long-term function and maintenance in the
patient. Similarly, a theoretical risk of any in vivo treatment
approach is that it may affect not only the transplanted cells
but also cells of the host, particularly surviving cancer cells,
which could be more receptive to stimulation. One advantage
of the brief ex vivo whole hCB unit incubation method is that
no long-term manipulation or cell isolation is required, and there456 Cell Stem Cell 8, 445–458, April 8, 2011 ª2011 Elsevier Inc.is limited potential of in vivo stimulation of persisting cancer cells
in the transplant recipient. Based on the data presented herein,
the FDA approved an investigational new drug (IND) application
for dmPGE2 in April 2009; this represents the first compound
discovered in zebrafish to be used in patients. An independently
conducted phase 1 clinical trial evaluating dmPGE2 in hCB
transplantation is in progress (http://clinicaltrials.gov/ct2/show/
NCT00890500). Further investigation will be needed to refine
the ex vivo treatment approach for optimal clinical use in multi-
center trials; furthermore, combinatorial strategies with other
bourgeoning therapies may prove to elicit the largest benefit
for the transplant patient while minimizing complications.
EXPERIMENTAL PROCEDURES
16,16-Dimethyl Prostaglandin E2
dmPGE2, purchased from Cayman Chemicals, was resuspended in DMSO
and diluted to working concentrations of 1 mM to 1 mM as indicated; ex vivo
dmPGE2 exposure duration was as indicated, followed by substrate removal
and washing prior to analysis or use.
hCB Samples
Xenotransplant studies utilized fresh whole hCB samples discarded from clin-
ical use (due to low cell number), obtained through the Center for Human Cell
Therapy (Dana-Farber Cancer Institute, Boston, MA) and the Carolinas Cord
Blood Bank (Duke University Medical Center, Durham, NC). After red cell
depletion (50%–60%) and FACS-based viability assessment, samples were
divided for parallel treatment. In vitro viability, proliferation, cell culture, and
gene expression analyses utilized frozen purified (CD34+, CD133+, MNC, or
HUVEC) deidentified hCB samples from pooled donors (Stem Cell Technolo-
gies). Cells were prepared to manufacturer’s directions, assessed for viability,
and split for use.
Apoptosis and Proliferation Analysis
5 million frozen CD34+ hCB cells were thawed, split, and treated with 1 mM
dmPGE2 or DMSO in 2% FCS in IMDM for 3, 6, or 9 hr at 37C. Apoptosis
was assessed by Annexin V-FITC (R&D Systems) and 7-AAD (BD PharMingen)
FACS. Proliferating cells were identified with the Click-iT EdU Flow Cytometry
Assay Kit (Invitrogen).
Colony Forming Units Culture
CD34+ CB cells were treated with DMSO or 1 mM dmPGE2 for 15 min, 30 min,
1 hr, 3 hr, or 6 hr in 2% FCS-supplemented IMDM at 37C. Cell suspensions
were mixed with MethoCult H4434 (Stem Cell Technologies), plated in tripli-
cate at limiting dilutions (2000, 800, or 320 cells per 33 mm plate/1.5 ml
H4434), and counted on day 13.
NOD/SCID Xenotransplantation
Individual whole or CD34-enriched hCB samples were split and exposed to
dmPGE2 (10 mM) or DMSO vehicle control ex vivo for 1 hr in dextran/albumin.
After sublethal irradiation (6.5Gy), 20 million whole or 2500 CD34+ hCB cells
were introduced by retroorbital injection into NOD/SCID (Charles River) recip-
ients, maintained and utilized according to approved IACUC protocols at
Children’s Hospital. PB was obtained at 1 and 3 months, and BMwas isolated
at >3 months posttransplant. After red cell lysis, hCD45 (Becton-Dickenson)
expression was examined by FACS; 1% PB and 0.2% BM hCB chimerism
were utilized to indentify positively engrafted recipients.
Quantitative PCR
CD34+ CB cells treated with DMSO or 1 mMdmPGE2 for 1 hr in IMDMwith 2%
FCS at 37Cwere washed and incubated for a fixed time (+2, 5, or 8 hr) prior to
RNA extraction (Trizol, Invitrogen). cDNA was synthesized with the Super-
Script III first-strand synthesis kit (Invitrogen). Quantitative RT-PCR (58C
annealing) was performed in triplicate with SybrGreen (Invitrogen) on the iQ5
Multicolor RTPCR Detection System (BioRad); primer sequences are listed
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PGE2 Enhances Human HSCsin Supplemental Experimental Procedures. Data were normalized to b-actin
and shown relative to DMSO at 1 hr postexposure.
Statistical Analysis
SigmaStat software was used for statistical analysis. Differences between
treatments for all in vitro and qPCR analyses were calculated by t test and
one-way ANOVA. hCB engraftment in NOD/SCID mice was analyzed by
Fisher’s exact test (one-tailed).
Nonhuman Primate Cell Collection
Rhesus macaques (Macaca mulata) were housed and handled in accordance
with the guidelines set by the Committee on Care and Use of Laboratory
Animals of the Institute of Laboratory Animal Resources, National Research
Council (DHHS publication No. NIH 85-23). PB HSCs were mobilized with
granulocyte colony-stimulating factor (G-CSF) and stem cell factor (gift of
Amgen), harvested by leukapheresis, and enriched for CD34+ cells as previ-
ously described (Donahue et al., 2005).
Human CD34+ Cell Collection
hMPBSCs were collected after G-CSF mobilization and enriched by CD34+
immunoselection according to IRB-approved protocols (02-H-0160, 96-H-
0049).
Microarray Analysis
Human and nonhuman primate MPBSCS were incubated with either 10 or 50
mMdmPGE2 in X-Vivomedia (Lonza) for 1 hr. Cells were collected at 6, 12, and
24 hr postincubation, and total RNA (Trizol extraction) was cohybridized to
custom-made 17.5K cDNA (UniGene cluster) microarrays. Hierarchical cluster
analysis and TreeView software were used for visualization. Gene clustering
analysis was performed with Ingenuity Pathway Analysis software.
Autologous Competitive Transplant Study
Rhesus macaques (n = 5) were mobilized daily with 10 mg/kg G-CSF and
200 mg/kg stem cell factor (SCF) for 5 days. On day 5, CD34+ enrichedMPBSC
were isolated from leukapheresed blood as described (Donahue et al., 2005).
CD34+ cells from each donor were split and transduced with a chimeric HIV
vector to express EGFP or EYFP (Uchida et al., 2009). Rhesus CD34+ cells
were treated with 10 mM dmPGE2 for 1 hr at 37C either prior to or after viral
transduction (Supplemental Experimental Procedures). Cells were reinfused
on day 3 after leukapheresis, after 2 consecutive days of 500 Gy total body
irradiation.
ACCESSION NUMBERS
The complete list of genes in the Hs-CCDTV-17.5k-1px printing are available in
the GEO database (http://nciarray.nci.nih.gov/galfiles) under the accession
number GSE27126.
SUPPLEMENTAL INFORMATION
Supplemental Information includes Supplemental Experimental Procedures,
seven figures, and seven tables and can be found with this article online at
doi:10.1016/j.stem.2011.02.003.
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